Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Madhulika Eluri"'
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
The development of acquired resistance to anti-EGFR therapies remains poorly understood, with most research to date exploring, and trying to overcome, various genomic mechanisms of resistance. However, recent work supports a model of resistance where
Externí odkaz:
https://doaj.org/article/78087fab0b044a409a49a51765c1fb0e
Autor:
Madhulika Eluri, BS, Ashley Feneran, DO, Jeremy S. Bordeaux, MD, MPH, Beth Ruben, MD, Stephen Ostrowski, MD, Boris C. Bastian, MD, Kord Honda, MD
Publikováno v:
JAAD Case Reports, Vol 3, Iss 2, Pp 131-134 (2017)
Externí odkaz:
https://doaj.org/article/beaf72f1189d420184b0db948b5f07f7
Publikováno v:
Clinical Cancer Research. 29:302-304
Summary Promising utility of using serial ctDNA in metastatic colorectal cancer to both refine patient selection, reduce toxicity due to chemotherapy, and to evaluate emerging resistance mechanisms may lead the way to novel therapeutic strategies. Ho
Autor:
Christine M. Parseghian, Ryan Sun, Melanie Woods, Stefania Napolitano, Hey Min Lee, Jumanah Alshenaifi, Jason Willis, Shakayla Nunez, Kanwal P. Raghav, Van K. Morris, John P. Shen, Madhulika Eluri, Alexey Sorokin, Preeti Kanikarla, Eduardo Vilar, Marko Rehn, Agnes Ang, Teresa Troiani, Scott Kopetz
PURPOSE Acquired resistance to anti–epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations in KRAS/NRAS/EGFR, among other MAPK-pathway membe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad7568a1d1d032bae5d1f98af201f2d0
https://hdl.handle.net/11591/497629
https://hdl.handle.net/11591/497629
Autor:
Christine M, Parseghian, Ryan, Sun, Melanie, Woods, Stefania, Napolitano, Hey Min, Lee, Jumanah, Alshenaifi, Jason, Willis, Shakayla, Nunez, Kanwal P, Raghav, Van K, Morris, John P, Shen, Madhulika, Eluri, Alexey, Sorokin, Preeti, Kanikarla, Eduardo, Vilar, Marko, Rehn, Agnes, Ang, Teresa, Troiani, Scott, Kopetz
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Acquired resistance to anti-epidermal growth factor receptor (EGFR) inhibitor (EGFRi) therapy in colorectal cancer (CRC) has previously been explained by the model of acquiring new mutations inWe analyzed paired plasma samples from patients withPatie
Autor:
Reagan Barnett, Sante Gnerre, Jason Willis, Michael J. Overman, Kanwal Pratap Singh Raghav, Christine Megerdichian Parseghian, Arvind Dasari, Maria Pia Morelli, Benny Johnson, Madhulika Eluri, Leylah Drusbosky, Scott Kopetz, Van K. Morris
Publikováno v:
Journal of Clinical Oncology. 41:186-186
186 Background: Actionable mutations can predict therapeutic benefit in patients with advanced malignancies, though clinical relevance of fusion testing for advanced colorectal cancer (aCRC) remains undefined. Identification of fusions from circulati
Autor:
Madhulika Eluri, Anaemy Danner De Armas, Jeffrey S. Ross, Radwa Sharaf, Dean C. Pavlick, Deyali Chatterjee, Milind M. Javle
Publikováno v:
Journal of Clinical Oncology. 41:607-607
607 Background: Microsatellite instability (MSI-H) and increased tumor mutation burden (TMB) have been associated with clinical benefit from immunotherapy. A small subset of patients with intrahepatic cholangiocarcinoma (iCCA) have microsatellite ins
Autor:
Christine Megerdichian Parseghian, Eduardo Vilar Sanchez, Ryan Sun, Madhulika Eluri, Van K. Morris, Benny Johnson, Maria Pia Morelli, Michael J. Overman, Jason Willis, Ryan Huey, Kanwal Pratap Singh Raghav, Arvind Dasari, Bryan K. Kee, Robert A. Wolff, John Paul Y.C. Shen, Scott Kopetz
Publikováno v:
Journal of Clinical Oncology. 40:3520-3520
3520 Background: In RAS/RAF WT colorectal cancer (CRC), rechallenge with anti-EGFR therapy (EGFRi) in patients (pts) with prior response leads to clinical benefit, with response rates up to 30% in prior trials. However, secondary MTs in the MAPK sign
Autor:
Liya Wang, Mukul Singhal, Madhulika Eluri, Adriana Valderrama, Bal Nepal, Shital Kamble, Michael Grabner, Usha Malhotra, Abby B. Siegel, Shilpi Swami, Milind M. Javle
Publikováno v:
Journal of Clinical Oncology. 40:4090-4090
4090 Background: BTC is associated with poor prognosis and limited treatment choices. There is limited evidence on HCRU and costs among BTC patients receiving systemic treatments (ST). This study examined HCRU and total direct cost of care among BTC
Publikováno v:
Journal of Clinical Oncology. 40:403-403
403 Background: The incidence of cholangiocarcinoma (CCA), particularly intrahepatic cholangiocarcinoma (IHC) has exponentially increased in the United States since 2007. While cholangiocarcinomas share some common characteristics, increasing evidenc